The study involves testing epcoritamab, administered subcutaneously, in combination with oral and intravenous anti-neoplastic agents. These include drugs like lenalidomide, ibrutinib, and polatuzumab ...

William Blair analysts project AbbVie to earn $16.15 per share by FY2028, a notable jump from its current $12.31 estimate.

AbbVie remains strong long-term performer, offering a solid dividend yield and robust revenue growth despite share price dips ...

Novartis' blockbuster immunology drug Cosentyx has disappointed in a phase 3 trial involving patients with giant cell ...

AbbVie is testing its oral drug upadacitinib in a Phase 3 trial for patients with hidradenitis suppurativa (HS) who failed ...

The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...

Genentech continues to study the drug in lung-scarring idiopathic pulmonary fibrosis as well as a new study in ulcerative colitis.

This study explored whether the rat F1 model of GvHD could induce an oral lichenoid reaction. While no overt oral mucosal abnormalities were observed, histology revealed diffuse subepithelial and ...

W. Timothy Garvey, M.D., served as lead author in the clinical trial. A new combination drug therapy is showing extraordinary promise in the bout against obesity, helping patients lose an average of ...

AbbVie, in collaboration with Roche-Genentech, is conducting a Phase 3 clinical study titled ‘Multicenter, Phase 3 Study of Venetoclax and Azacitidine as Maintenance Therapy for Patients With ...

NEW STUDY IDENTIFIES ADDITIONAL LINKS BETWEEN POULTRY ANTIBIOTIC USE AND HUMAN DRUG RESISTANCE Provided by GlobeNewswire Jun 25, 2025, 4:22:58 AM ...